OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics
PENNINGTON, and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer immunotherapies, today announced that it has licensed…
Celularity Announces Dosing of First Patient in Phase I Study of Human Placental Hematopoietic Stem Cell-Derived Natural Killer Cells (CYNK-001) in Adults with Recurrent Glioblastoma Multiforme (GBM) and E-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
FLORHAM PARK, , Nov. 24, 2020 /PRNewswire/ -- Celularity, Inc., a clinical-stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, announced today that the first…
Cactus Communications Partners with Wiley to Support Journal Authors and Editorial Offices with UNSILO Technical Checks in the Screening of Manuscripts
PRINCETON, , Nov. 24, 2020 /PRNewswire/ -- Cactus Communications (CACTUS), a technology company accelerating scientific advancement, has signed an enterprise agreement with John Wiley and Sons Inc., a leader in research…